Zimbabue - inglés - Medicines Control Authority

sandoz sa (pty) - hydroxycarbamide - tablet, coated; oral - 1000mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

nova laboratories limited, united kingdom - hydroxycarbamide - oral solution - 100 mg/ml,

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - hydroxycarbamide - capsule, hard - 200 mg,

Filipinas - inglés - FDA (Food And Drug Administration)

n/a; importer: medinova pharmaceutical inc.; distributor: medinova pharmaceutical inc. - hydroxycarbamide - capsule - 500mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - hydroxycarbamide - capsule, hard - 500 mg,

Unión Europea - maltés - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Portugal - portugués - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - hidroxicarbamida - cápsula - 500 mg - hidroxicarbamida 500 mg - hydroxycarbamide - genérico - duração do tratamento: longa duração

Portugal - portugués - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

medac gesellschalft fur klinische spezialpraparate gmbh - hidroxicarbamida - cápsula - 500 mg - hidroxicarbamida 500 mg - hydroxycarbamide - n/a - duração do tratamento: longa duração

Portugal - portugués - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

medac gesellschalft fur klinische spezialpraparate gmbh - hidroxicarbamida - cápsula - 500 mg - hidroxicarbamida 500 mg - hydroxycarbamide - n/a - duração do tratamento: longa duração

Unión Europea - francés - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémie, drépanocytose - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.